paf

PAF (C16) is a potent MAPK and MEK/ERK activator that induces increased vascular permeability. PAF (C16) (PAF (C16)) is a platelet-activating factor, a phospholipid-derived mediator and a ligand for PAF G protein-coupled receptor (PAFR). PAF (C16) has shown anti-apoptotic and anti-inflammatory activity in vitro, inhibiting Caspase-dependent apoptosis by interacting with its receptor (PAF-R) to perform cell signaling.

PAF-AN-1 is a novel potent platelet-activating factor receptor (PAF) antagonist involved in the study of anaphylactic death.

PAF C-18 is a naturally occurring phospholipid molecule belonging to the platelet-activating factor (PAF) family, which acts as an intercellular signaling molecule involved in platelet aggregation, vasodilatation, and inflammatory responses.PAF C-18 is involved in hemostasis and thrombosis by binding to its specific G-protein-coupled receptor (PAFR) and activating.

Azelaoyl PAF is a potent PPARγ agonist that competitively binds thiazolidinediones with potency comparable to rosiglitazone. In atherosclerosis studies, Azelaoyl PAF promotes the uptake of oxidized low-density lipoprotein (oxLDL) by macrophages by upregulating CD36 expression. In fibroblasts from Friedreich's ataxia (FRDA) patients, Azelaoyl PAF significantly increased mRNA and protein levels of ferritin.

Methylcarbamyl PAF C-16 (Carbamyl-PAF) is a platelet-activating factor analogue with PAF agonist properties, activating inflammation in pregnancy tissues and promoting preterm birth.

C18:1 Lyso PAF is a reagent used in biochemical reactions.

Setipafant is an antagonist of the platelet-activating factor.

Lyso-PAF C-16 is a substrate for PAF C-16, also obtainable via enzymatic acylation of arachidonic acid, suitable for biochemical experiments.

Dihomo-γ-Linolenoyl PAF C-16 is a PAF analogue that incorporates dihomo-γ-linolenoate at the sn-2 position instead of the acetate moiety found in PAF C-16.

Rupatadine Fumarate (Rinialer) (UR-12592 Fumarate) is a potent dual PAF/H1 antagonist with Ki of 0.55/0.1 uM.

CMI-392 is a dual inhibitor of 5-lipoxygenase and a receptor antagonist for platelet-activating factor (PAF) with IC50 values of 100 nM and 10 nM, respectively.

E-6123 is an antagonist of platelet-activating factor (PAF) receptor.

Ro 24-4736 is an effective and selective platelet-activating factor antagonist.

Homoeriodictyol 7-O-β-D-glucoside (Homoeriodictyol 7-O-glucoside) is a natural product derived from Viscum coloratum (Kom.) Nakai and acts as an antagonist of platelet-activating factor (PAF).

48740 RP (RP 55779) is an antagonist of platelet-activating factor.

CP-96486 is a potent and orally active antagonist of leukotriene D4 (LTD4) and platelet activating factor (PAF) receptors, with inhibitory constants (Kis) of 20 and 24 nM, respectively.

DF-1111301 is a novel anti-allergic compound with anti-histamine H1 and anti-PAF activity.

SDZ-62-434, a platelet-activating factor inhibitor with antitumor activity, inhibits bombesin- and platelet-derived growth factor-induced DNA synthesis in quiescent Swiss 3T3 cells, making it a potential candidate for studying leukemia, human xenograft colorectal cancer, and lung cancer.

Dersalazine (Dersalazine Free Base), an inhibitor of platelet-activating factor, exerts intestinal anti-inflammatory activity in different rodent types of colitis by down-regulating IL-17 expression, with potential efficacy in patients with ulcerative colitis.

YM-264 is a selective and orally active antagonist of platelet-activating factor (PAF) (pKi value of 8.85 for rabbit platelet membranes).

1-O-Hexadecyl-2-arachidonoyl-sn-glycero-3-PC undergoes acylation through the action of CoA-independent transacylase, transforming lyso-PAF C-16 into this compound. It serves as the predominant precursor in the biosynthesis of PAF C-16 via the remodeling pathway.

1-Cinnamoylpyrrolidine, a natural product prepared from Piper caninum, can be used as a DNA strand breaking agent, inducing the relaxation of the plasmid pBR322 DNA superhelix in the presence of Cu2+. 1-Cinnamoylpyrrolidine inhibits PAF-induced platelet aggregation with an IC50 value of 37.3 μM. value was 37.3 μM.

6-Deoxyjacareubin exhibits potent antioxidant and antifungal activities. 6-Deoxyjacareubin inhibits platelet activating factor (PAF) receptor with an IC50 of 29.0 microM and can be used in studies about natural PAF receptor antagonists.

Methylcarbamyl PAF C-8 is resistant to degradation by PAF-AH and has a half-life of over 100 minutes in platelet-poor plasma, exhibiting platelet aggregation activity. In NRK-49 cells overexpressing PAF receptor, it induces the expression of c-myc, c-fos, and activates mitogen-activated protein kinase (MAPK). Furthermore, Methylcarbamyl PAF C-8 can induce G1 phase cell cycle arrest. This compound shows potential for research in cardiovascular and anti-cancer applications.